{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:27:02Z","timestamp":1788319622539,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T00:00:00Z","timestamp":1561680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T00:00:00Z","timestamp":1561680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s40272-019-00332-y","type":"journal-article","created":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T02:02:55Z","timestamp":1561687375000},"page":"291-301","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Safety and Tolerability of Adjunctive Brivaracetam in Pediatric Patients\u2009<\u200916 Years with Epilepsy: An Open-Label Trial"],"prefix":"10.1007","volume":"21","author":[{"given":"Edwin","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanne","family":"Dilley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda","family":"McDonough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armel","family":"Stockis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,28]]},"reference":[{"issue":"9","key":"332_CR1","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.braindev.2008.01.007","volume":"30","author":"H Hwang","year":"2008","unstructured":"Hwang H, Kim KJ. New antiepileptic drugs in pediatric epilepsy. Brain Dev. 2008;30(9):549\u201355.","journal-title":"Brain Dev."},{"issue":"1","key":"332_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/epi.12433","volume":"55","author":"V Biton","year":"2014","unstructured":"Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, Johnson ME, Lu S. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia. 2014;55(1):57\u201366.","journal-title":"Epilepsia."},{"issue":"12","key":"332_CR3","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1111\/epi.13212","volume":"56","author":"P Klein","year":"2015","unstructured":"Klein P, Schiemann J, Sperling MR, Whitesides J, Liang W, Stalvey T, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015;56(12):1890\u20138.","journal-title":"Epilepsia."},{"issue":"1","key":"332_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/epi.12432","volume":"55","author":"P Ryvlin","year":"2014","unstructured":"Ryvlin P, Werhahn KJ, Blaszczyk B, Johnson ME, Lu S. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia. 2014;55(1):47\u201356.","journal-title":"Epilepsia."},{"key":"332_CR5","unstructured":"UCB, Brussels, Belgium. Briviact\u00ae US Prescribing information. 2018.  \nhttps:\/\/www.ucb.com\/_up\/ucb_com_products\/documents\/Briviact_20180510_US-PI.pdf\n\n. Accessed 5 June 2019."},{"key":"332_CR6","unstructured":"UCB, Brussels, Belgium. Summary of product characteristics Briviact\u00ae (EU).  \nhttps:\/\/www.ema.europa.eu\/en\/documents\/product-information\/briviact-epar-product-information_en.pdf\n\n. Accessed 5 June 2019."},{"issue":"1","key":"332_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1365-2125.2008.03158.x","volume":"66","author":"P Rolan","year":"2008","unstructured":"Rolan P, Sargentini-Maier ML, Pigeolet E, Stockis A. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol. 2008;66(1):71\u20135.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"332_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1124\/dmd.107.017129","volume":"36","author":"ML Sargentini-Maier","year":"2008","unstructured":"Sargentini-Maier ML, Espi\u00e9 P, Coquette A, Stockis A. Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos. 2008;36(1):36\u201345.","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"332_CR9","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1111\/epi.13433","volume":"57","author":"A Stockis","year":"2016","unstructured":"Stockis A, Hartstra J, Mollet M, Hadi S. Bioavailability and bioequivalence comparison of brivaracetam 10, 50, 75, and 100\u00a0mg tablets and 100\u00a0mg intravenous bolus. Epilepsia. 2016;57(8):1288\u201393.","journal-title":"Epilepsia."},{"issue":"5","key":"332_CR10","doi-asserted-by":"publisher","first-page":"394","DOI":"10.2133\/dmpk.DMPK-14-RG-010","volume":"29","author":"A Stockis","year":"2014","unstructured":"Stockis A, Watanabe S, Rouits E, Matsuguma K, Irie S. Brivaracetam single and multiple rising oral dose study in healthy Japanese participants: influence of CYP2C19 genotype. Drug Metab Pharmacokinet. 2014;29(5):394\u20139.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"8","key":"332_CR11","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1124\/dmd.112.045328","volume":"40","author":"JM Nicolas","year":"2012","unstructured":"Nicolas JM, Chanteux H, Rosa M, Watanabe S, Stockis A. Effect of gemfibrozil on the metabolism of brivaracetam in vitro and in human subjects. Drug Metab Dispos. 2012;40(8):1466\u201372.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"332_CR12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/cpdd.275","volume":"6","author":"C Otoul","year":"2017","unstructured":"Otoul C, Watanabe S, McCabe S, Stockis A. Relative bioavailability and bioequivalence of brivaracetam 10\u00a0mg\/mL oral solution and 50-mg film-coated tablet. Clin Pharmacol Drug Dev. 2017;6(3):313\u20137.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"6","key":"332_CR13","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00228-017-2230-6","volume":"73","author":"R Schoemaker","year":"2017","unstructured":"Schoemaker R, Wade JR, Stockis A. Brivaracetam population pharmacokinetics in children with epilepsy aged 1\u00a0month to 16 years. Eur J Clin Pharmacol. 2017;73(6):727\u201333.","journal-title":"Eur J Clin Pharmacol"},{"key":"332_CR14","unstructured":"No authors. Pediatric news. J Pediatr Pharmacol Ther. 2016;21(1):98."},{"key":"332_CR15","unstructured":"European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment of epileptic disorders. 2010. \nhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/01\/WC500070043.pdf\n\n. Accessed 12 Jan 2018."},{"issue":"4","key":"332_CR16","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.spen.2010.10.002","volume":"17","author":"GD Anderson","year":"2010","unstructured":"Anderson GD. Developmental pharmacokinetics. Semin Pediatr Neurol. 2010;17(4):208\u201313.","journal-title":"Semin Pediatr Neurol."},{"issue":"7","key":"332_CR17","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s40262-017-0597-2","volume":"57","author":"R Schoemaker","year":"2018","unstructured":"Schoemaker R, Wade JR, Stockis A. Extrapolation of a brivaracetam exposure-response model from adults to children with focal seizures. Clin Pharmacokinet. 2018;57(7):843\u201354.","journal-title":"Clin Pharmacokinet"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-019-00332-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-019-00332-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-019-00332-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T02:45:13Z","timestamp":1593225913000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-019-00332-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,28]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["332"],"URL":"https:\/\/doi.org\/10.1007\/s40272-019-00332-y","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,28]]},"assertion":[{"value":"28 June 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was funded by UCB Pharma. UCB Pharma was responsible for the design and conduct of the trial, the collection, analysis, and interpretation of data, and was involved in the preparation and review of the manuscript. The authors made the final decision to submit the manuscript for publication. Open access was funded by UCB Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Edwin Liu has no conflicts of interest that are directly relevant to the content of this article. Deanne Dilley was an employee of UCB Pharma when the trial was conducted and is currently employed by Statistics and Data Corporation. Belinda McDonough was an employee of UCB Pharma when the trial was conducted and is currently Director of MAFSAF Ltd. She has received stocks and stock options from UCB Pharma. Armel Stockis and Tony Daniels are employees of UCB Pharma. Armel Stockis has received stock options from UCB Pharma. Tony Daniels has received stocks from UCB Pharma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Informed consent was obtained from all individual participants included in the trial.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Due to the small sample size in this trial, individual patient data cannot be adequately anonymized and there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}}]}}